Article
Public, Environmental & Occupational Health
Philine Fabel, Theresa Wolf, Helena Zyber, Julian Rubel, Maria C. Jockers-Scheruebl
Summary: This article evaluates the treatment outcomes of acute psychiatric patients before and after the implementation of Soteria-elements in an acute psychiatric ward. The implementation resulted in a connected locked and open area, enabling continuous milieu therapeutic treatment. The results show a decrease in locked ward time, an increase in open ward time, an increase in treatment discontinuation without an increase in re-admissions, and a reduction of antipsychotic medication for patients with schizophrenia spectrum disorder.
FRONTIERS IN PUBLIC HEALTH
(2023)
Article
Pharmacology & Pharmacy
Tzu-Hua Wu, Chieh-Hsin Lin, Kah Kheng Goh, Cynthia Yi-An Chen, Chun-Hsin Chen, Hsien-Yuan Lane, Mong-Liang Lu
Summary: The study assessed the relationship between prolactin levels and sexual dysfunction in schizophrenia patients using olanzapine. Hyperprolactinemia, sexual dysfunction, and metabolic syndrome were prevalent, with factors such as gender, age, and insulin levels being associated with these conditions. Female patients had higher levels of sexual dysfunction, while male patients had lower prolactin levels.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Psychiatry
Christian Schmidt-Kraepelin, Sandra Feyerabend, Christina Engelke, Mathias Riesbeck, Eva Meisenzahl-Lechner, Pablo-Emilio Verde, Christoph U. Correll, Michael Kluge, Christian Makiol, Andrea Neff, Christina Lange, Susanne Englisch, Mathias Zink, Berthold Langguth, Timm B. Poeppl, Dirk Reske, Euphrosyne Gouzoulis-Mayfrank, Gerhard Gruender, Alkomiet Hasan, Anke Brockhaus-Dumke, Markus Jaeger, Jessica Baumgaertner, Stefan Leucht, Joachim Cordes
Summary: This study aimed to compare the effectiveness of a combination of amisulpride plus olanzapine with either intervention as a monotherapy. The results showed that the combination therapy had better symptom reduction after 8 weeks. However, the combination treatment may lead to more side effects.
Article
Psychiatry
Yaxue Wu, Yanli Li, Weiye Liang, Luyuan Bai, Jianjin Yu, Keqing Li, Yunshu Zhang, Yanmei Guo, Zenglong Liu, Jian Wang, Congpei Zhang, Xijin Wang, Jia Xu, Liping Liu, Juan Li, Fude Yang
Summary: This multicenter study conducted in China evaluated the efficacy and safety of ziprasidone sequential treatment through intramuscular/oral routes in agitated patients with schizophrenia. The results showed that ziprasidone IM demonstrated significant reduction in agitation, and sequential oral formulation ensured stability and continuation of the treatment. Ziprasidone sequential therapy may provide a new approach for acute agitation in schizophrenic patients.
Article
Psychiatry
Sanya Sharma, Ajeet Sidana, Shivangi Mehta, Manoj Kumar Bajaj
Summary: Aripiprazole and olanzapine have the potential to improve specific domains of neurocognitive profile in patients with schizophrenia, with aripiprazole showing better improvement in mental speed and visual-spatial constructive ability, and olanzapine showing better improvement in performance of category fluency and verbal fluency.
INDIAN JOURNAL OF PSYCHIATRY
(2023)
Article
Psychiatry
Chih-Min Liu, Chen -Chung Liu, Ming-Hsien Hsieh, Tzung-Jeng Hwang, Yi-Ting Lin, Yi-Ling Chien, Hai-Gwo Hwu
Summary: The plasma level of C4A decreased with aripiprazole treatment, and the decrease rate was associated with the treatment response of the positive dimension in patients with early psychosis.
PSYCHIATRY RESEARCH
(2022)
Article
Psychiatry
Renata Alisauskiene, Erik Johnsen, Rolf Gjestad, Rune A. Kroken, Eirik Kjelby, Igne Sinkeviciute, Farivar Fathian, Inge Joa, Solveig Klaebo Reitan, Maria Rettenbacher, Else-Marie Loberg
Summary: This study investigated the influence of drug use on the effectiveness of antipsychotic medication in patients with schizophrenia spectrum disorders (SSD). The results showed no significant differences in effectiveness among the three studied antipsychotics, regardless of drug use. However, older patients in the drug use group showed greater reduction in PANSS positive subscale score during treatment with amisulpride. Therefore, amisulpride may be a suitable choice for older patients with drug use.
GENERAL HOSPITAL PSYCHIATRY
(2023)
Review
Psychiatry
Giulia Paris, Irene Bighelli, Giacomo Deste, Spyridon Siafis, Johannes Schneider-Thoma, Yikang Zhu, John M. Davis, Antonio Vita, Stefan Leucht
Summary: This network meta-analysis evaluated the efficacy of short-acting IM second-generation antipsychotic drugs in patients with schizophrenia and schizophrenia-like disorders presenting acute agitation. The results showed that ziprasidone, olanzapine, aripiprazole, and haloperidol were more effective than placebo in calming patients at 2 hours. Olanzapine was somewhat more efficacious than aripiprazole.
SCHIZOPHRENIA RESEARCH
(2021)
Article
Nursing
Linjie Li, Yu Zhang, Peng Wang, Weelic Chong, Yang Hai, Ping Xu, Fang Fang
Summary: This study found that in acutely ill patients, conservative oxygen therapy was not associated with decreased mortality compared to liberal oxygen therapy, and there were no significant differences in good functional outcomes between the two oxygen therapies.
INTERNATIONAL JOURNAL OF NURSING STUDIES
(2021)
Article
Psychiatry
Huimei An, Hongzhen Fan, Yajun Yun, Song Chen, Siyuan Qi, Botao Ma, Jing Shi, Zhiren Wang, Fude Yang
Summary: This study aimed to explore the relationship between metabolic parameters and plasma concentrations of olanzapine (OLA) and its metabolite, 4-N'-desmethyl-olanzapine (DMO), in patients with schizophrenia on therapeutic doses. The results showed that lower plasma DMO concentrations were associated with higher glucose and triglyceride levels, while higher plasma OLA concentrations were associated with increased levels of C-reactive protein and homocysteine. Regular measurement of metabolic parameters and drug monitoring of OLA and DMO are recommended in patients with schizophrenia receiving OLA treatment.
FRONTIERS IN PSYCHIATRY
(2022)
Review
Clinical Neurology
Muhammad Youshay Jawad, Yazen Alnefeesi, Leanna M. W. Lui, Felicia Ceban, David C. J. Chen-Li, Kayla Teopiz, Saja Jaberi, Emily S. Gillissie, Joshua D. Di Vincenzo, Joshua D. Rosenblat, Roger S. McIntyre
Summary: The combination treatment of OLZ/SAM is associated with reduced weight gain compared to OLZ monotherapy in adults with schizophrenia. It retains similar clinical efficacy as OLZ with improved tolerability.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Psychiatry
Tianhang Zhou, Chengcheng Pu, Zetao Huang, Tianqi Gao, Enpeng Zhou, Yue Zheng, Dan Zhang, Bingjie Huang, Zhang Cheng, Chuan Shi, Xin Yu
Summary: This study assessed weight changes following antipsychotic treatment in first-episode schizophrenia patients and compared the effects of aripiprazole, risperidone, and olanzapine. The results showed that body weight increased at an average rate of 0.93% per month, with the highest growth rate in the first 3 months. Clinically relevant weight gain (CRW) was observed in 79% of patients. Olanzapine was associated with significantly higher weight gain compared to risperidone and aripiprazole. Predictors for first-year CRW included smaller baseline BMI, family history of mental disorder, receiving olanzapine, and CRW in the first month. Aripiprazole may not be the ideal choice for long-term metabolic side effects.
ASIAN JOURNAL OF PSYCHIATRY
(2023)
Article
Medicine, Research & Experimental
Rose-Marie Rebillard, Marc Charabati, Camille Grasmuck, Abdelali Filali-Mouhim, Olivier Tastet, Nathalie Brassard, Audrey Daigneault, Lyne Bourbonniere, Sai Priya Anand, Renaud Balthazard, Guillaume Beaudoin-Bussieres, Romain Gasser, Mehdi Benlarbi, Ana Carmena Moratalla, Yves Carpentier Solorio, Marianne Boutin, Negar Farzam-kia, Jade Descoteaux-Dinelle, Antoine Philippe Fournier, Elizabeth Gowing, Annemarie Laumaea, Helene Jamann, Boaz Lahav, Guillaume Goyette, Florent Lemaitre, Victoria Hannah Mamane, Jeremie Prevost, Jonathan Richard, Karine Thai, Jean-Francois Cailhier, Nicolas Chomont, Andres Finzi, Michael Chasse, Madeleine Durand, Nathalie Arbour, Daniel E. Kaufmann, Alexandre Prat, Catherine Larochelle
Summary: Dysregulation of immune cell subsets was found in both acute SARS-CoV-2 infection and non-COVID-19 related acute illnesses, while specific differences were identified in certain myeloid and lymphocyte subsets associated with SARS-CoV-2 status. Some SARS-CoV-2-specific immune alterations correlated with disease severity, disease outcome at 30 days, and mortality.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Pharmacology & Pharmacy
Lei Zhao, Hua Liu, Wenjuan Wang, Youping Wang, Meihong Xiu, Shuyun Li
Summary: This study aimed to evaluate the relationship between changes in plasma levels of L-carnitine metabolites and cognitive improvement after olanzapine treatment. Participants were 25 female patients with first episode schizophrenia who received 4 weeks of olanzapine monotherapy. Results showed that cognitive improvement was associated with changes in L-carnitine metabolite levels, particularly reduced butyrylcarnitine levels.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Economics
Vincent K. C. Yan, Miriam Haendler, Hayden Lau, Xue Li, Kim S. J. Lao, Sik-Hon Tsui, Celene Y. L. Yap, Martin R. J. Knapp, Esther W. Chan
Summary: This study compared the cost-effectiveness of intramuscular (IM) olanzapine, haloperidol, and midazolam for the management of acutely agitated patients in Hong Kong Accident and Emergency (A&E) departments. The results showed that IM midazolam was the dominant cost-effective treatment, while IM olanzapine could be considered as an alternative to IM haloperidol.